Exactly. This pattern is obvious to anyone objectively looking at this stock. Nader makes some declaration with aggressive timelines and the sheep eat it up. Not long after that, he comes up with some new indication which he tosses out just before he starts to backpedal on previous promises. This happens over and over and I really can't understand how naive you one has to be to keep buying into this.
With respect to the company and the viability of it going forward and delivering Leronlimab to the market and a waiting patient population: COPD- doesn't matter. NASH- doesn't matter. GvHD- DOES NOT MATTER . Get the BLA approved and then we can go save the world with our miracle drug.